Supplementing Hearing Aid Use with Auditory Training

for

A Randomized Control Trial:

Supplementing Hearing Aid Use with Auditory Training

Gabrielle H. Saunders, Sherri L. Smith, Theresa H. Chisolm, Melissa T. Frederick, Rachel A. McArdle, and Richard H. Wilson

SDC Table 1 ... 2

SDC Table 2 ... 4

SDC Table 3 ... 5

SDC Table 4 ... 6

SDC Table 5 ... 7

SDC Table 6 ... 8

SDC Table 7 ... 9

SDC Table 8 ... 10

SDC Table 1. Mean pure-tone thresholds (dB HL), standard deviations, and ranges for the left and right ears of the four intervention groups, the two hearing-aid user groups, and all participants combined.

Group and Frequency (Hz)

User Status 250 500 1000 1500 2000 3000 4000 6000 8000

Left Ear

LACE-DVD

New Mean 20.8 21.5 27.1 35.3 44.6 58.8 65.1 68.8 69.6

SD 10.7 9.5 10.3 11.3 15.4 12.3 11.5 15.2 16.9

Range 5-50 5-45 10-45 10-65 15-70 25-85 45-90 40-105 35-110

Exp. Mean 21.2 22.8 28.4 35.7 45.7 57.2 63.4 64.5 66.4

SD 8.7 8.0 13.6 14.5 14.7 11.8 9.7 13.3 16.5

Range 5-40 5-35 5-60 15-65 20-70 35-75 40-85 35-100 30-110 LACE-C

New Mean 20.5 22.1 25.6 33.1 40.9 57.9 65.9 67.9 69.1

SD 7.7 8.5 11.0 13.8 12.6 13.0 13.0 14.9 18.6

Range 5-35 5-40 10-55 5-70 20-70 30-85 40-95 40-95 25-110

Exp. Mean 20.6 21.6 32.0 40.8 47.8 58.6 63.4 64.6 63.6

SD 8.6 9.1 10.9 12.9 13.5 13.0 14.4 16.7 17.2

Range 10-40 5-10 15-55 20-70 20-70 25-85 40-100 35-100 35-110 Placebo

New Mean 22.1 22.2 26.4 33.2 40.1 56.8 65.8 68.7 68.6

SD 10.5 10.6 10.1 11.8 15.6 14.4 14.8 17.3 16.8

Range 0-45 5-50 10-50 15-65 15-70 30-90 35-100 30-100 30-110

Exp. Mean 23.4 24.0 29.0 37.1 43.2 58.7 66.8 67.2 66.5

SD 8.3 9.6 9.5 13.4 16.2 12.9 11.9 13.6 17.3

Range 10-45 5-50 15-50 10-65 10-65 30-85 30-95 35-95 30-110 Control

New Mean 19.7 22.8 27.0 35.1 41.8 55.0 63.9 66.6 66.3

SD 9.2 11.2 12.2 13.0 13.5 14.0 13.3 16.9 19.6

Range 5-40 5-50 5-50 10-50 10-65 25-80 35-95 35-110 25-110

Exp. Mean 19.8 22.6 28.4 35.7 45.5 60.9 67.8 70.2 69.5

SD 9.0 10.2 12.0 14.1 15.5 18.6 16.7 17.9 19.7

Range 5-50 5-45 5-50 15-60 15-75 20-100 25-95 30-110 35-110 Data combined across intervention groups

New Mean 20.7 22.2 26.6 34.2 41.9 57.1 65.1 68.0 68.3

SD 9.5 9.9 10.9 12.5 14.3 13.4 13.1 16.0 17.9

Range 0-50 5-50 5-55 5-70 10-70 25-90 35-100 30-110 25-110

Exp. Mean 21.4 22.8 29.4 37.2 45.4 58.8 65.5 66.7 66.6

SD 8.7 9.2 11.5 13.7 15.0 14.2 13.3 15.3 17.6

Range 5-50 5-50 5-60 10-70 10-75 20-100 25-100 30-110 30-110

SDC Table 1, continued

Right Ear LACE-DVD

New Mean 20.4 22.6 25.9 33.2 43.6 59.5 65.4 70.4 70.3

SD 8.5 9.5 9.5 11.7 14.8 15.9 16.3 17.5 19.0

Range 5-35 5-45 10-45 10-55 10-65 25-110 25-110 25-110 20-105

Exp. Mean 22.6 22.4 27.9 35.0 43.8 58.6 62.8 67.9 68.8

SD 10.6 8.6 12.7 15.6 13.7 11.9 11.5 15.1 17.5

Range 5-45 5-35 10-60 10-65 15-65 25-75 40-85 40-95 40-110 LACE-C

New Mean 21.8 22.4 26.5 31.5 38.7 53.8 63.3 65.6 67.1

SD 9.4 9.0 11.3 13.3 14.8 14.6 13.8 15.6 20.1

Range 0-45 0-40 5-50 10-65 10-75 25-85 30-90 30-110 20-110

Exp. Mean 20.8 21.2 28.0 36.2 46.6 59.8 63.6 64.8 67.4

SD 9.8 10.1 11.0 12.8 13.1 11.2 16.5 15.8 17.0

Range 10-50 0-40 10-50 20-70 25-65 40-85 30-100 25-100 35-110 Placebo

New Mean 20.9 21.8 27.1 31.8 40.5 57.1 66.7 67.8 70.0

SD 11.7 10.5 10.0 11.8 15.5 17.6 17.4 17.9 16.4

Range 0-60 5-45 5-45 5-55 5-70 20-90 30-110 30-110 40-110

Exp. Mean 23.7 25.1 28.8 36.6 43.1 58.2 66.2 69.1 66.6

SD 8.3 8.8 10.0 14.5 17.2 15.5 16.1 15.6 19.3

Range 10-50 5-40 10-50 10-65 15-70 25-85 30-105 35-95 25-110 Control

New Mean 20.3 22.3 26.9 33.2 40.8 55.5 62.7 65.6 67.2

SD 8.3 9.2 10.1 12.2 13.8 13.3 13.9 17.7 19.6

Range 5-35 5-45 5-45 10-60 10-65 25-80 30-95 30-110 20-105

Exp. Mean 22.2 23.8 26.6 36.7 47.6 60.5 67.4 68.8 72.1

SD 9.5 11.0 12.4 12.7 12.7 16.4 17.7 17.0 17.8/

Range 5-55 10-55 5-50 10-60 25-65 20-90 25-95 25-95 25-110 Data combined across intervention groups

New Mean 20.8 22.3 26.6 32.5 40.9 56.4 64.5 67.3 68.6

SD 9.5 9.5 10.1 12.2 14.7 15.4 15.3 17.2 18.7

Range 0-60 0-45 5-50 5-65 5-75 20-110 25-110 25-110 20-110

Exp. Mean 22.4 23.3 27.9 36.2 45.1 59.2 65.1 67.8 68.7

SD 9.4 9.6 11.4 13.9 14.4 14.0 15.5 15.8 17.9

Range 5-50 0-55 5-60 10-70 15-70 20-90 25-105 25-100 25-110

SDC Table

2

. Means (dB SNR) and standard deviations for the WIN by intervention group and user group for each visit.

Group and V2 V3 V4

User Status Mean SD Mean SD Mean SD

LACE-DVD

New 9.6 2.3 8.8 2.8 9.4 2.2

Experienced 10.0 2.1 9.1 1.8 9.2 2.3

LACE-C

New 9.8 2.5 8.9 2.7 9.3 2.4

Experienced 10.0 2.9 9.5 2.7 9.7 2.5

Placebo

New 9.6 2.2 9 1.8 9.1 2.4

Experienced 9.8 2.5 8.9 2.3 9.6 2.3

Control

New 10.1 2.1 9.5 2.3 9.8 2.1

Experienced 10.7 2.4 9.7 2.4 9.8 2.4

All

New 9.8 2.3 9 2.4 9.4 2.2

Experienced 10.1 2.5 9.3 2.3 9.6 2.4

SDC Table

3

. Means (percent correct) and standard deviations for TCST 45%-CR and 65%- CR by intervention and user group for each visit.

Group and V2 V3 V4

User Status Mean SD Mean SD Mean SD

TCST 45%-CR LACE-DVD

New 69.4 15.7 72.3 16.3 72.2 18.0

Experienced 69.7 15.7 76.6 12.1 77.0 12.2

LACE-C

New 71.9 15.6 75.1 14.3 75.4 11.9

Experienced 68.5 15.0 71.7 18.2 68.7 19.7

Placebo

New 68.0 13.9 75.2 13.2 71.4 16.9

Experienced 69.3 14.4 73.0 15.3 70.3 15.9

Control

New 68.2 16.1 70.3 16.3 69.7 16.3

Experienced 62.2 18.4 67.8 15.2 69.8 17.3

All

New 69.3 15.3 73.1 15.1 72.1 15.9

Experienced 67.5 16.0 72.3 15.4 71.5 16.5

TCST 65%-CR LACE-DVD

New 46.5 13.5 51.2 16.0 51.9 15.3

Experienced 44.5 19.3 52.9 13.9 51.2 15.5

LACE-C

New 47.9 15.0 54.1 13.7 51.4 14.3

Experienced 47.9 15.1 53.3 15.3 48.5 16.5

Placebo

New 44.0 15.9 46.6 15.1 46.2 18.2

Experienced 45.5 14.8 48.3 16.0 49.4 17.9

Control

New 45.9 16.1 45.8 15.1 46.1 18.8

Experienced 43.5 17.7 45.5 15.1 45.6 14.5

All

New 46.1 15.1 49.3 15.2 48.9 16.8

Experienced 45.3 16.7 49.8 15.3 48.7 16.1

SDC Table

4

. Means (50% point--dB S/N) and standard deviations for NU20-CM by intervention and user group for each visit.

Group and V2 V3 V4

User Status Mean SD Mean SD Mean SD

LACE-DVD

New 6.9 3.4 5.5 3.8 6.3 3.3

Experienced 6.4 4.0 4.9 3.2 5.1 3.6

LACE-C

New 6.1 3.9 5.2 4.1 5.1 3.5

Experienced 7.4 4.5 5.3 4.6 7.1 4.5

Placebo

New 5.9 3.8 5.8 3.6 5.6 4.5

Experienced 6.5 4.2 5.5 4.1 6.1 4.6

Control

New 7.3 3.9 6.4 3.4 6.5 3.6

Experienced 7.2 4.2 6.3 4.0 6.3 3.7

All

New 6.6 3.8 5.7 3.7 5.9 3.7

Experienced 6.9 4.2 5.5 4.0 6.1 4.1

SDC Table

5

. Means (number of digits recalled) and standard deviations for DS-Forward and DS-Backwards by intervention and user group for each visit.

Group and V2 V3 V4

User Status Mean SD Mean SD Mean SD

DS-Forward LACE-DVD

New 8.4 1.3 9.0 2.1 8.7 1.7

Experienced 8.2 1.6 8.6 1.8 8.6 1.8

LACE-C

New 7.9 1.2 8.2 1.2 8.4 1.7

Experienced 8.5 1.7 8.3 1.8 8.4 1.8

Placebo

New 7.9 1.1 8.7 1.4 8.0 1.5

Experienced 8.5 1.5 8.6 1.6 9.0 1.7

Control

New 8.2 1.7 8.6 2.1 8.2 1.9

Experienced 8.4 1.6 8.3 1.3 8.8 1.7

All

New 8.1 1.4 8.6 1.8 8.3 1.7

Experienced 8.4 1.6 8.4 1.6 8.7 1.7

DS-Backward LACE-DVD

New 5.0 1.6 5.4 1.8 4.8 1.8

Experienced 4.8 1.8 4.8 2.1 5.3 1.9

LACE-C

New 4.9 1.8 5.1 1.6 4.9 1.3

Experienced 5.0 1.8 4.8 1.8 4.7 1.8

Placebo

New 5.3 1.7 5.1 1.7 5.5 1.4

Experienced 5.1 1.4 5.0 1.7 5.2 1.5

Control

New 5.2 1.9 5.3 2.0 4.7 1.7

Experienced 5.3 1.9 4.8 1.8 5.3 2.0

All

New 5.1 1.7 5.2 1.8 5.0 1.6

Experienced 5.0 1.7 4.9 1.8 5.1 1.8

SDC Table

6

. Means (difference between the HP and LP 50% points in dB) and standard deviations of the Linguistic Context Use scores from the multi-SNR R-SPIN by intervention and user group for each visit.

Group and V2 V3 V4

User Status Mean SD Mean SD Mean SD

LACE-DVD

New 5.0 2.0 4.6 1.9 4.1 1.8

Experienced 4.5 1.8 4.7 2.0 4.2 1.8

LACE-C

New 4.4 1.5 4.6 1.6 4.6 1.3

Experienced 4.9 2.0 5.3 1.7 4.8 1.9

Placebo

New 5.3 2.0 5.2 2.2 4.7 2.0

Experienced 5.1 2.1 4.6 2.0 4.7 2.1

Control

New 5.6 2.2 4.7 2.2 4.4 1.9

Experienced 5.5 2.3 4.9 2.2 5.0 2.4

All

New 5.1 2.0 4.8 2.0 4.4 1.7

Experienced 5.0 2.1 4.9 2.0 4.7 2.1

SDC Table

7

. Mean and standard deviation (points) of APHAP Global score by intervention and user group for each visit.

Group and V2 V3 V4

User Status Mean SD Mean SD Mean SD

LACE-DVD

New 29.8 21.5 27.5 19.4 27.2 18.3

Experienced 34.8 12.3 33.6 14.0 33.7 17.9

LACE-C

New 27.3 16.3 28.8 14.9 31.2 17.0

Experienced 36.3 19.4 34.6 18.2 36.1 18.5

Placebo

New 31.9 14.6 28.3 15.1 30.8 19.2

Experienced 35.7 16.5 35.6 16.9 35.5 18.2

Control

New 32.8 18.9 28.4 15.2 33.8 16.5

Experienced 40.4 17.5 38.8 17.0 36.7 16.4

All

New 30.6 18.0 28.3 16.0 30.8 17.7

Experienced 36.7 16.5 35.7 16.5 35.5 17.6

SDC Table

8

. Mean and standard deviation (points) of HHI total scores by intervention and user group for each visit.

Group and V2 V3 V4

User Status Mean SD Mean SD Mean SD

LACE-DVD

New 24.6 23.1 21.8 22.2 19.5 17.3

Experienced 34.2 22.1 29.5 17.1 28.7 22.1

LACE-C

New 30.7 23.2 23.4 24.1 27.4 23.7

Experienced 31.9 20.7 35.3 22.0 28.3 18.4

Placebo

New 25.1 18.3 26.3 17.0 24.9 20.3

Experienced 34.8 22.0 33.8 21.6 30.7 18.8

Control

New 30.2 21.5 25.2 19.4 29.3 21.6

Experienced 37.4 20.3 33.5 21.9 35.6 22.4

All

New 27.8 21.6 24.2 20.7 25.3 20.9

Experienced 34.6 21.2 33.0 20.7 30.7 20.5